PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease

European Journal of Neuroscience

Volumn 29, Issue 5, 2009, Pages 954-963

  Schintu, Nicoletta ^a   Frau, Lucia ^a   Ibba, Marcello ^a   Caboni, Pierluigi ^a   Garau, Arianna ^a   Carboni, Ezio ^a   Carta, Anna R ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Dopamine; Glia; Inflammation; Motor behaviour; MPP+; Tyrosine hydroxylase

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3,4 DIHYDROXYPHENYLACETIC ACID; CD11B ANTIGEN; DOPAMINE; DYNORPHIN; GLIAL FIBRILLARY ACIDIC PROTEIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROBENECID; ROSIGLITAZONE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; ENCEPHALITIS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MACROGLIA; MALE; MICROGLIA; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN; SMELLING; SUBSTANTIA NIGRA;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; ANTIGENS, CD11B; CATALEPSY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; DOPAMINE; DRUG INTERACTIONS; DYNORPHINS; GENE EXPRESSION REGULATION; GLIAL FIBRILLARY ACIDIC PROTEIN; GLOBUS PALLIDUS; LOCOMOTION; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; MPTP POISONING; PPAR GAMMA; PSYCHOMOTOR PERFORMANCE; RNA, MESSENGER; SMELL; TANDEM MASS SPECTROMETRY; THIAZOLIDINEDIONES; TYROSINE 3-MONOOXYGENASE;

EID: 61449237400     PISSN: 0953816X     EISSN: 14609568     Source Type: Journal    
DOI: 10.1111/j.1460-9568.2009.06657.x     Document Type: Article

References (71)

1. Anglade, P., Mouatt-Prigent, A., Agid, Y. Hirsch, E. (1996) Synaptic plasticity in the caudate nucleus of patients with Parkinson's disease. Neurodegeneration, 5, 121 128.
2. Barcia, C., Fernández Barreiro, A., Poza, M. Herrero, M.T. (2003) Parkinson's disease and inflammatory changes. Neurotox. Res., 5, 411 418.
3. Barcia, C., Sánchez Bahillo, A., Fernández-Villalba, E., Bautista, V., Poza, Y., Poza, M., Fernández-Barreiro, A., Hirsch, E.C. Herrero, M.T. (2004) Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure. Glia, 46, 402 409.
4. Bernardo, A. Minghetti, L. (2006) PPAR-gamma agonists as regulators of microglial activation and brain inflammation. [Review]. Curr. Pharm. Des., 12, 93 109.
5. Bernardo, A. Minghetti, L. (2008) Regulation of glial cell functions by PPAR-gamma Natural and synthetic agonists. PPAR Res., 2008, 864140.
6. Bezard, E., Imbert, C., Deloire, X., Bioulac, B. Gross, C.E. (1997) A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey. Brain Res., 766, 107 112.
7. Bezard, E., Dovero, S., Imbert, C., Boraud, T. Gross, C.E. (2000) Spontaneous long-term compensatory dopaminergic sprouting in MPTP-treated mice. Synapse, 38, 363 368.
8. Blanchard, V., Chritin, M., Vyas, S., Savasta, M., Feuerstein, C., Agid, Y., Javoy-Agid, F. Raisman-Vozari, R. (1995) Long-term induction of tyrosine hydroxylase expression: compensatory response to partial degeneration of the dopaminergic nigrostriatal system in the rat brain. J. Neurochem., 64, 1669 1679.
9. Braak, H., Del Tredici, K., Rüb, U., de Vos, R.A., Jansen Steur, E.N. Braak, E. (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging, 24, 197 211.
10. Braissant, O., Foufelle, F., Scotto, C., Dauça, M. Wahli, W. (1996) Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology, 137, 354 366.
11. Breidert, T., Callebert, J., Heneka, M.T., Landreth, G., Launay, J.M. Hirsch, E.C. (2002) Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J. Neurochem., 82, 615 624.
12. Bush, T.G., Puvanachandra, N., Horner, C.H., Polito, A., Ostenfeld, T., Svendsen, C.N., Mucke, L., Johnson, M.H. Sofroniew, M.V. (1999) Leukocyte infiltration, neuronal degeneration, and neurite outgrowth after ablation of scar-forming, reactive astrocytes in adult transgenic mice. Neuron, 23, 297 308.
13. Carboni, E., Silvagni, A., Vacca, C. Di Chiara, G. (2006) Cumulative effect of norepinephrine and dopamine carrier blockade on extracellular dopamine increase in the nucleus accumbens shell, bed nucleus of stria terminalis and prefrontal cortex. J. Neurochem., 96, 473 481.
14. Carta, A.R., Tronci, E., Pinna, A. Morelli, M. (2005) Different responsiveness of striatonigral and striatopallidal neurons to L-DOPA after a subchronic intermittent L-DOPA treatment. Eur. J. Neurosci., 21, 1196 1204.
15. Chase, T.N. Oh, J.D. (2000) Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci., 23, S86 S91.
16. Chaturvedi, R.K. Beal, M.F. (2008) PPAR: a therapeutic target in Parkinson's disease. J. Neurochem., 106, 506 518.
17. Chung, J.H., Seo, A.Y., Chung, S.W., Kim, M.K., Leeuwenburgh, C., Yu, B.P. Chung, H.Y. (2008) Molecular mechanism of PPAR in the regulation of age-related inflammation. Ageing Res. Rev., 7, 126 136.
18. Colburn, R.W., DeLeo, J.A., Rickman, A.J., Yeager, M.P., Kwon, P. Hickey, W.F. (1997) Dissociation of microglial activation and neuropathic pain behaviors following peripheral nerve injury in the rat. J. Neuroimmunol., 79, 163 175.
19. Cristiano, L., Bernardo, A. Cerù, M.P. (2001) Peroxisome proliferator-activated receptors (PPARs) and peroxisomes in rat cortical and cerebellar astrocytes. J. Neurocytol., 30, 671 683.
20. Cullingford, T.E., Bhakoo, K., Peuchen, S., Dolphin, C.T., Patel, R. Clark, J.B. (1998) Distribution of mRNAs encoding the peroxisome proliferator-activated receptor alpha, beta, and gamma and the retinoid X receptor alpha, beta, and gamma in rat central nervous system. J. Neurochem., 70, 1366 1375.
21. Dehmer, T., Heneka, M.T., Sastre, M., Dichgans, J. Schulz, J.B. (2004) Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J. Neurochem., 88, 494 501.
22. Di Monte, D.A., McCormack, A., Petzinger, G., Janson, A.M., Quik, M. Langston, W.J. (2000) Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model. Mov. Disord., 15, 459 466.
23. Drew, P.D., Xu, J., Storer, P.D., Chavis, J.A. Racke, M.K. (2006) Peroxisome proliferator-activated receptor agonist regulation of glial activation: relevance to CNS inflammatory disorders. [Review]. Neurochem. Int., 49, 183 189.
24. Fernagut, P.O., Chalon, S., Diguet, E., Guilloteau, D., Tison, F. Jaber, M. (2003) Motor behaviour deficits and their histopathological and functional correlates in the nigrostriatal system of dopamine transporter knockout mice. Neuroscience, 116, 1123 1130.
25. Fleming, S.M., Salcedo, J., Fernagut, P.O., Rockenstein, E., Masliah, E., Levine, M.S. Chesselet, M.F. (2004) Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J. Neurosci., 24, 9434 9440.
26. Fornai, F., Schlüter, O.M., Lenzi, P., Gesi, M., Ruffoli, R., Ferrucci, M., Lazzeri, G., Busceti, C.L., Pontarelli, F., Battaglia, G., Pellegrini, A., Nicoletti, F., Ruggieri, S., Paparelli, A. Südhof, T.C. (2005) Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc. Natl. Acad. Sci. USA, 102, 3413 3418.
27. García-Bueno, B., Caso, J.R., Pérez-Nievas, B.G., Lorenzo, P. Leza, J.C. (2007) Effects of peroxisome proliferator-activated receptor gamma agonists on brain glucose and glutamate transporters after stress in rats. Neuropsychopharmacology, 32, 1251 1260.
28. Gerfen, C.R. (2003) D1 dopamine receptor supersensitivity in the dopamine-depleted striatum animal model of Parkinson's disease. Neuroscientist, 9, 455 462.
29. Haehner, A., Hummel, T., Hummel, C., Sommer, U., Junghanns, S. Reichmann, H. (2007) Olfactory loss may be a first sign of idiopathic Parkinson's disease. Mov. Disord., 22, 839 842.
30. Heneka, M.T., Klockgether, T. Feinstein, D.L. (2000) Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. J. Neurosci., 20, 1.
31. Heneka, M.T., Landreth, G.E. Hüll, M. (2007) Drug insight: effects mediated by peroxisome proliferator-activated receptor-gamma in CNS disorders. Nat. Clin. Pract. Neurol., 3, 496 504.
32. Hirsch, E.C., Breidert, T., Rousselet, E., Hunot, S., Hartmann, A. Michel, P.P. (2003) The role of glial reaction and inflammation in Parkinson's disease. Ann. N Y Acad. Sci., 991, 214 228.
33. Jung, T.W., Lee, J.Y., Shim, W.S., Kang, E.S., Kim, S.K., Ahn, C.W., Lee, H.C. Cha, B.S. (2006) Rosiglitazone protects human neuroblastoma SH-SY5Y cells against acetaldehyde-induced cytotoxicity. Biochem. Biophys. Res. Commun., 340, 221 227.
34. Jung, T.W., Lee, J.Y., Shim, W.S., Kang, E.S., Kim, S.K., Ahn, C.W., Lee, H.C. Cha, B.S. (2007) Rosiglitazone protects human neuroblastoma SH-SY5Y cells against MPP+ induced cytotoxicity via inhibition of mitochondrial dysfunction and ROS production. J. Neurol. Sci., 253, 53 60.
35. el-Kebbi, I.M., Roser, S. Pollet, R.J. (1994) Regulation of glucose transport by pioglitazone in cultured muscle cells. Metabolism, 43, 953 958.
36. Kiaei, M., Kipiani, K., Chen, J., Calingasan, N.Y. Beal, M.F. (2005) Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp. Neurol., 191, 331 336.
37. Klotz, L., Schmidt, M., Giese, T., Sastre, M., Knolle, P., Klockgether, T. Heneka, M.T. (2005) Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor gamma levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients. J. Immunol., 175, 4948 4955.
38. Kowall, N.W., Hantraye, P., Brouillet, E., Beal, M.F., McKee, A.C. Ferrante, R.J. (2000) MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. Neuroreport, 11, 211 213.
39. Kurkowska-Jastrzebska, I., Wrońska, A., Kohutnicka, M., Członkowski, A. Członkowska, A. (1999) The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse. Exp. Neurol., 156, 50 61.
40. Langston, J.W., Forno, L.S., Tetrud, J., Reeves, A.G., Kaplan, J.A. Karluk, D. (1999) Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann. Neurol., 46, 598 605.
41. Luo, Y., Yin, W., Signore, A.P., Zhang, F., Hong, Z., Wang, S., Graham, S.H. Chen, J. (2006) Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. J. Neurochem., 97, 435 448.
42. Manning-Bog, A.B. Langston, J.W. (2007) Model fusion, the next phase in developing animal models for Parkinson's disease. Neurotox. Res., 11, 219 240.
43. McGeer, P.L., Itagaki, S., Boyes, B.E. McGeer, E.G. (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology, 38, 1285 1291.
44. McGeer, P.L., Schwab, C., Parent, A. Doudet, D. (2003) Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-l,2, 3,6-tetrahydropyridine administration. Ann. Neurol., 54, 599 604.
45. McGeer, P.L. McGeer, E.G. (2008) Glial reactions in Parkinson's disease. Mov. Disord., 23, 474 483.
46. Meredith, G.E. Kang, U.J. (2006) Behavioral models of Parkinson's disease in rodents: a new look at an old problem. [Review]. Mov. Disord., 21, 1595 1606.
47. Meredith, G.E., Totterdell, S., Petroske, E., Santa Cruz, K., Callison, R.C. Jr. Lau, Y.S. (2002) Lysosomal malfunction accompanies alpha-synuclein aggregation in a progressive mouse model of Parkinson's disease. Brain Res., 22, 156 165.
48. Meredith, G.E., Dervan, A.G. Totterdell, S. (2005) Activated microglia persist in the substantia nigra of a chronic MPTP mouse model of Parkinson's disease. In Bolam, J.P., Ingham, C.A. Magill, P.J Eds The Basal Ganglia VIII. Springer Science, Singapore.
49. Mitsumoto, Y., Watanabe, A., Mori, A. Koga, N. (1998) Spontaneous regeneration of nigrostriatal dopaminergic neurons in MPTP-treated C57BL/6 mice. Biochem. Biophys. Res. Commun., 248, 660 663.
50. Moreno, S., Farioli-Vecchioli, S. Cerù, M.P. (2004) Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience, 123, 131 145.
51. Myer, D.J., Gurkoff, G.G., Lee, S.M., Hovda, D.A. Sofroniew, M.V. (2006) Essential protective roles of reactive astrocytes in traumatic brain injury. Brain, 129, 2761 2772.
52. Novikova, L., Garris, B.L., Garris, D.R. Lau, Y.S. (2006) Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease. Neuroscience, 140, 67 76.
53. Park, E.J., Park, S.Y., Joe, E.H. Jou, I. (2003) 15d-PGJ2 and rosiglitazone suppress Janus kinase-STAT inflammatory signaling through induction of suppressor of cytokine signaling 1 (SOCS1) and SOCS3 in glia. J. Biol. Chem., 278, 14747 14752.
54. Park, S.W., Yi, J.H., Miranpuri, G., Satriotomo, I., Bowen, K., Resnick, D.K. Vemuganti, R. (2007) Thiazolidinedione class of peroxisome proliferator-activated receptor gamma agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats. J. Pharmacol. Exp. Ther., 320, 1002 1012.
55. Paxinos, G. Franklin, K.B.J., editors 2001) The Mouse Brain in Stereotaxic Coordinates, 2nd edition. Academic Press, San Diego, CA.
56. Petroske, E., Meredith, G.E., Callen, S., Totterdell, S. Lau, Y.S. (2001) Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment. Neuroscience, 106, 589 601.
57. Quinn, L.P., Crook, B., Hows, M.E., Vidgeon-Hart, M., Chapman, H., Upton, N., Medhurst, A.D. Virley, D.J. (2008) The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B. Br. J. Pharmacol., 154, 226 233.
58. Rogers, J., Mastroeni, D., Leonard, B., Joyce, J. Grover, A. (2007) Neuroinflammation in Alzheimer's disease and Parkinson's disease: are microglia pathogenic in either disorder? [Review]. Int. Rev. Neurobiol., 82, 235 246.
59. Romera, C., Hurtado, O., Mallolas, J., Pereira, M.P., Morales, J.R., Romera, A., Serena, J., Vivancos, J., Nombela, F., Lorenzo, P., Lizasoain, I. Moro, M.A. (2007) Ischemic preconditioning reveals that GLT1/EAAT2 glutamate transporter is a novel PPARgamma target gene involved in neuroprotection. J. Cereb. Blood Flow Metab., 27, 1327 1338.
60. Schmidt, N. Ferger, B. (2001) Neurochemical findings in the MPTP model of Parkinson's disease. J. Neural Transm., 108, 1263 1282.
61. Smith, U. (2001) Pioglitazone mechanism of action. Int J. Clin. Pract. Suppl., 121, 13 18.
62. Sofroniew, M.V. (2005) Reactive astrocytes in neural repair and protection. Neuroscientist, 11, 400 407.
63. Strum, J.C., Shehee, R., Virley, D., Richardson, J., Mattie, M., Selley, P., Ghosh, S., Nock, C., Saunders, A. Roses, A. (2007) Rosiglitazone induces mitochondrial biogenesis in mouse brain. J. Alzheimer Dis., 11, 45 51.
64. Teismann, P. Ferger, B. (2001) Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse, 39, 167 174.
65. Woster, A.P. Combs, C.K. (2007) Differential ability of a thiazolidinedione PPARgamma agonist to attenuate cytokine secretion in primary microglia and macrophage-like cells. J. Neurochem., 103, 67 76.
66. Wu, D.C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D.K., Ischiropoulos, H. Przedborski, S. (2002) Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine mouse model of Parkinson disease. J. Neurosci., 22, 1763 1771.
67. Xu, J. Drew, P.D. (2007) Peroxisome proliferator-activated receptor-gamma agonists suppress the production of IL-12 family cytokines by activated glia. J. Immunol., 178, 1904 1913.
68. Yan, Q., Zhang, J., Liu, H., Bbu-Khan, S., Vassar, R., Biere, A.L., Citron, M. Landreth, G. (2003) Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J. Neurosci., 23, 7504 7509.
69. Yazdani, U., German, D.C., Liang, C.L., Manzino, L., Sonsalla, P.K. Zeevalk, G.D. (2006) Rat model of Parkinson's disease: chronic central delivery of 1-methyl-4-phenylpyridinium (MPP+). Exp. Neurol., 200, 172 183.
70. Youdim, M.B. Arraf, Z. (2004) Prevention of MPTP (N-methyl-4-phenyl-1,2, 3,6-tetrahydropyridine) dopaminergic neurotoxicity in mice by chronic lithium: involvements of Bcl-2 and Bax. Neuropharmacology, 46, 1130 1140.
71. Zhao, Y., Patzer, A., Herdegen, T., Gohlke, P. Culman, J. (2006) Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats. FASEB J., 20, 1162 1175.